APA (7th ed.) Citation

TF, C., CDS, S., L, A., R, R., AVE, C., CC, S. d. C., . . . LKM, O. (2025). Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: Results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais brasileiros de dermatologia, 100(2), 260. https://doi.org/10.1016/j.abd.2024.08.002

Chicago Style (17th ed.) Citation

TF, Cestari, et al. "Efficacy and Safety of Risankizumab Versus Methotrexate in Patients with Moderate-to-severe Plaque Psoriasis: Results from IMMbrace, a Randomized, Double-blind, Phase 3 Study with an Open-label Extension Period in Brazil." Anais Brasileiros De Dermatologia 100, no. 2 (2025): 260. https://doi.org/10.1016/j.abd.2024.08.002.

MLA (9th ed.) Citation

TF, Cestari, et al. "Efficacy and Safety of Risankizumab Versus Methotrexate in Patients with Moderate-to-severe Plaque Psoriasis: Results from IMMbrace, a Randomized, Double-blind, Phase 3 Study with an Open-label Extension Period in Brazil." Anais Brasileiros De Dermatologia, vol. 100, no. 2, 2025, p. 260, https://doi.org/10.1016/j.abd.2024.08.002.